TerrAscend Stock (CSE: TER) (OTCQX: TRSSF) - Investor Dashboard

Summary

Financials (03/31/20)

Capital Structure (05/28/20)

TerrAscend provides quality products, brands, and services to the global cannabinoid market. As the first North American Operator (NAO), with scale operations in both Canada and the US, the Company participates in the medical and legal adult use market across Canada and in several US states where cannabis has been legalized for therapeutic or adult use.

Additionally, TerrAscend is the first and only cannabis company with sales in Europe as well as the US and Canada as it has received EU GMP certification for its manufacturing facility in Mississauga, Ontario.

Highlights

• Canadian LP with global distribution; multi-state operator in the U.S.; nationwide distributor of hemp-derived CBD products; and drug development and R&D platform
• Management comprised of leaders from healthcare, pharmaceutical, banking, cannabis and online grocery industries
• Strategic investors include Canopy Growth, Canopy Rivers, and JW Funds
• $80.5 million loan from strategic partner Canopy Growth
• Unique ability to sell THC and CBD products within Canada, the U.S., and the European Union through TerrAscend’s manufacturing footprint
• Brand portfolio including premium cannabis Haven St., Valhalla Confections, Funky Farms CBD extracts, Original Hemp, Knüba Naturals, State Flower, and Ilera

Growth Strategy

• Focus on developing protectable intellectual property assets
• Creating quality brands that resonate with patients and consumers
• Multi-state operator (MSO) in the U.S. strongly positioned in the markets where it competes: California, Nevada, Pennsylvania and New Jersey
• Plans to leverage The Apothecarium Dispensary brand and store model across the U.S.
• Canadian LP concentrating on production and manufacturing of cannabinoid products for medical and adult-use consumers
• Global export from EU GMP certified indoor cannabis facility in Mississauga, Ontario, Canada
• U.S. nationwide distribution of hemp-derived CBD products through Arise Bioscience
• R&D strategy supported by Ascendant Laboratories and Solace RX

Differentiators

• First operator with scaled operations in both the U.S. and Canada, and first and only cannabis company with sales in the U.S., Canada and Europe
• One of six entities granted a permit to apply for a vertically integrated license in New Jersey, with TerrAscend located in the attractive North region
• Significant market share in Pennsylvania’s limited license market via Ilera Healthcare, one of five super license holders in the state
• Entrance into Utah with a processor license
• Developing drug preparation premises (DPP) facility for non-cannabinoid formulations
• Leverage proximity to Toronto to distribute on behalf of third-party LPs, with same-day delivery capabilities
• Wholesale supply agreements with seven Canadian provinces
• Proven consolidator with M&A expertise in the highly fragmented U.S. cannabis industry

Advancing Research

• Emphasis on developing protectible intellectual property
• Advancing plant genetics and product formulations
• Pharma-grade manufacturing facility

Building Brands

• Developing trusted and recognized brands; seven owned brands
• Addressing needs of multiple cannabis business streams
• Defining brands based on deep consumer insights

Promoting Responsibility

• Ensuring highest standard of ethics and corporate integrity
• Advocating responsible use of products
• Exceeding industry and regulatory standards

Optimizing Wellness

• Providing support for medical cannabis use
• Guiding cannabis selection and consumption preferences
• Enhancing the therapeutic application of cannabinoids

Robert Fagan
GMP Securities

Glenn. G. Mattson
Ladenburg Thalmann

Noel Atkinson
Clarus Securities

Eric Des Lauriers, CFA
Craig-Hallum Capital Group

Kenric S. Tyghe
AltaCorp Capital